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ABSTRACT  We  have  recently reported  a specific dose-dependent  stimulation  of  posttransla- 
tional incorporation of tyrosine into tubulin ~x-chains  of rabbit peritoneal leukocytes as induced 
by the synthetic peptide chemoattractant formyl-methionyl-leucyl-phenylalanine  (FMLP). The 
present study reports a similar, specific stimulation  of tubulin tyrosinolation  in  human  poly- 
morphonuclear  leukocytes  (PMN).  When  compared  to  normal  PMN,  both  the  resting  and 
FMLP-stimutated  levels  of  posttranslational  tyrosine  incorporation  were  two-  to  threefold 
higher in PMN of three patients with the Chediak-Higashi syndrome (CHS). The concentration 
of cellular  tubutin and  the specific activity of tubulin  tyrosine ligase were similar in  PMN of 
CHS  patients and  normal  donors and  resembled  that of other non-neuronal  cells.  The  high 
levels of tyrosine incorporation in PMN of CHS patients were normalized by the administration 
of ascorbate,  both  in  in vitro and  in  in vivo experiments.  In vitro addition of ascorbate  also 
inhibited  the  FMLP-induced  stimulation  of  tyrosine incorporation  in  both  normal  and  CHS 
cells. Normalization of higher levels of tyrosine incorporation in PMN of CHS patients and the 
inhibition of  FMLP-induced  stimulation  of tubulin  tyrosinolation in  normal  and CHS cells  as 
observed  with  ascorbate  could  also  be  affected  by other  reducing  agents  such  as  reduced 
glutathione, cysteine, or dithiothreitol. These results  suggest a possible  relationship between 
cellular redox and tubulin tyrosinolation in PMN. 
Tubulin is subject to a reversible posttranslational modification 
whereby a  tyrosine residue  is added to the carboxy-terminal 
glutamate of tubulin a-chain (2, 37). The enzyme that catalyzes 
this ATP-dependent reaction,  tubulin  tyrosine ligase (ligase), 
has been detected in both vertebrate  (3,  38)  and invertebrate 
(22) tissues.  Another distincly different enzyme, carboxypepti- 
dase tubulin (CPT), which is believed to be the major cellular 
enzyme responsible  for the  removal of the carboxy-terminal 
tyrosine of tubulin,  has also been detected and characterized 
(1,  23).  Although the  presence  of the tyrosine has  not been 
found to affect the assembly of microtubules in vitro, it  has 
been clearly demonstrated  that  the 6S dimeric tubulin  is the 
substrate for the ligase (21),  whereas the detyrosinolating en- 
zyme preferentially acts on intact microtubules (23). Moreover, 
we  have  observed  changes  in  the  state  of tyrosinolation  of 
tubulin  in cells  undergoing cytoskeletal rearrangements such 
as in differentiating neuronal cells (29) and in Hela cells during 
mitosis  (34).  Recently, we have studied  the levels of tubulin 
tyrosinolation  in  rabbit  peritoneal  leukocytes  and  have  re- 
ported (32) a specific,  dose-dependent stimulation induced by 
the  synthetic  peptide  chemoattractant  formyl-methionyl-leu- 
cyl-phenylalanine (FMLP). The FMLP-induced stimulation of 
tubulin tyrosinolation in rabbit leukocytes seems to be medi- 
ated via receptors and depends on normally functioning path- 
ways of protein  and  phospholipid  methylation (32).  The re- 
sponse  is  also  abolished  by a  variety of reagents  which  are 
known  to  be  chemotactic  inhibitors.  These  results  strongly 
suggest  a  functional link between  leukocyte chemotaxis and 
tubulin tyrosinolation (32). 
Microtubules have been implicated in leukocyte chemotaxis 
(20,  26,  36),  and  they  are  believed  to  be  essential  for  the 
formation, orientation, and maintenance ofpseudopods during 
the response of the polymorphonuclear leukocytes (PMN) to 
chemotactic stimuli (26).  Our recent findings with rabbit leu- 
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in human peripheral blood PMN.  We have also studied and 
compared the levels of tubulin tyrosinolation in PMN isolated 
from Chediak-Higashi syndrome (CHS) patients with those of 
normal PMN.  CHS  is a  rare  disorder characterized  by giant 
granules in most granule-containing cells (45, 46). Clinically, 
the disease can evolve into a lymphomalike phase with death 
at  an  early  age;  patients  not  developing  lymphoma  usually 
develop  severe  peripheral  neuropathy  by age  25  (45,  46).  A 
major clinical expression is marked susceptibility to pyogenic 
infections,  which,  in the absence  of a  defect  in humoral  im- 
munity, has directed attention to phagocytic cells and mono- 
cytes (45, 46). The patients are neutropenic (46), and PMN and 
monocytes isolated from CHS patients have been reported to 
have  defective  chemotactic  responses  (10,  17)  and  delayed 
bactericidal  activity (39)  despite  increased  oxidative  metabo- 
lism (40). These abnormalities have often been associated with 
impaired microtubule function in these cells (6, 35). 
The present investigation was undertaken to study the effect 
of FMLP on human PMN  tubulin tyrosinolation and also to 
compare the reaction in PMN from CHS patients with that of 
normal PMN.  Effects  of addition of various reducing  agents 
like ascorbate,  reduced glutathione (GSH),  cysteine,  or dithi- 
othreitol (DTT) were also studied in normal and CHS PMN. 
During the course of this investigation, a protease (or peptidase) 
activity was also detected in the particulate fractions of human 
PMN,  which  was  found to  be  reduced  significantly  in  CHS 
patients.  While a preliminary report of this work has appeared 
(33), details of these experiments and possible functional  im- 
plications  of the results are described  in the present commu- 
nication. 
MATERIALS  AND  METHODS 
Preparation of PMN 
Heparinized human peripheral blood,  either from normal donors or CHS 
patients, was separated into a granulocyte-rich fraction by Hypaque-Ficoll and 
dextran sedimentation techniques (8). This generally resulted in a  cell fraction 
containing over 95% PMN with >95% viability as determined by the exclusion of 
trypan blue dye. Most of the PMN from CHS patients were obtained from two 
brothers with CHS, who have been extensively studied and described (46). In 
this paper, they will be referred to as CHS~ and CHS2. We have also had occasion 
to study a third, unrelated, CHS patient, whom we shall refer to as CHS3, who 
has also been reported previously (45). 
Posttransla tional Incorporation of [t 4  C] Tyrosine 
in Human PMN 
Freshly fractionated normal or CHS PMN, suspended in Hanks's balanced 
salt solution or in Gey's medium, were collected by centrifugation at 1,000 g for 
5 min. The supernatant was aspirated, and the packed ceils were gently resus- 
pended  at  a  cell  density of  107/ml  in  an  isoosmotic  medium  as  previously 
described (29) with bovine serum albumin (BSA) added to a final concentration 
of 0.1%. All other experimental conditions were identical to those described for 
rabbit leukocytes (32). Before the addition of[14C]tyrosine, the ceils were routinely 
incubated with antibiotics (32) for 30 min at 37°C, which effectively inhibited 
protein synthesis to >99%, without inhibiting chemotaxis. 
To study the effect of FMLP on posttranslational incorporation of tyrosine 
into PMN tubulin in intact ceils, we have generally used a cell density of 107/ml 
with FMLP concentration at 10  -7 M. Although chemotaxis was studied at a lower 
cell density of 2.5 x  10  ~ cells/mL the higher concentration of cells was necessary 
to obtain enough material for reliable determination of [14C]tyrosine incorpora- 
tion under our experimental conditions. Unless indicated otherwise, the various 
agents to be tested were present during the 30-min preincubation with antibiotics. 
In some experiments where the effect of oral administration of a large dosage 
of ascorbate (8 g) on tyrosine incorporation in CHS cells was studied, peripheral 
blood from the CHS patients was obtained before and 2 h  after administration 
of the ascorbate. The blood levels of ascorbate were also determined at both 
times. 
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Other Analytical Procedures 
Most of the experimental procedures used in the current study with human 
PMN  were used in  our previous work with rabbit leukocytes and have been 
described in detail (32). 
For the ligase assay, freshly separated PMN (~6 ×  107 cells) were collected by 
centrifugation at 1,000 g for 5 rain and resuspended in 0.5 ml of an isotonic buffer 
containing 0.34 M sucrose, 25 mM HEPES, 0.5 mM MgSO4, and 1 mM (DTT), 
adjusted to pH 7.2. The cells were disrupted by mild sonication (29) and ligase 
specific activity was determined in the 100,000-g  superuatant and pellet fractions 
of the cell-sonicates as previously described (32). The carboxypeptidase (CPT) 
activity was assayed according to the experimental conditions previously reported 
from our laboratory (23). The  100,000-g supernatant and pellet fractions were 
obtained as described for the ligase assay, except for using a tubulin reassembly 
buffer (i.e.,  100 mM K + 2-[N-morpholino] ethane sulfonic acid,  l  mM EGTA, 
and 0.5 mM MgSo4, pH 6.8). to resuspend the cells before they were sonicated 
and centrifuged. 
The  procedures  for the  determination  of the  specific  radioactivity of the 
intracellular tyrosine pool in  normal and CHS  PMN  were identical to  those 
described for rabbit leukocytes (32). Briefly, the various samples of PMN were 
incubated with [14C]-labeled tyrosine in the presence of antibiotics and rapidly 
filtered and washed with ice-cold phosphate-buffered saline before extraction 
with 7% TCA. The TCA extracts were lyophilized and reconstituted in desired 
volume  of distilled  water.  Equal  aliquots of each sample  were  analyzed  for 
tyrosine (by amino acid analyses in a Durrum amino acid analyzer) and radio- 
activity. Where indicated, the PMN were preincubated with  10 7 M  FMLP for 
60 min. 
Native  tubulin  concentration was determined  by colchicine binding assay 
using Whatman DE-23 ion-exchange cellulose columns. The details of the assay 
have been  reported  (23).  For quantitation of the  amount of radioactivity in 
tubulin bands of normal and CHS ceils, the  fluorogram was scanned using a 
quick-scan R  and D  densitometer (Helena Laboratories, Beaumont, TX). The 
final recordings were photocopied, and the peak areas (corresponding to tubulin) 
were cut out and weighed. Polyacrylamide slab gel electrophoresis was performed 
in an SDS urea system as described by Eipper (11). Cell preparation for the gel 
electrophoresis and processing of the gels for detection of radiolabeled protein 
bands by fluorography (24) were similar to those described for rabbit leukocytes 
(32). Chemotaxis was routinely measured as previously described (14). Protein 
was determined by the procedure of Lowry et al. (25) standardized with BSA. 
[14C]Tyrosinolated tubulin was prepared by the enzymatic tyrosinolation of 
tubulin  by ligase  as  recently described  (23).  [:3H]Valine  labeled  tubulin  was 
prepared from l-d-old rat brains after intracranial injections of [:~H]valine via 
protein synthesis. The details of the method have been described elsewhere !30). 
RESULTS 
Ligase and Colchicine Binding Activity 
The specific activity of ligase in the 100,000-g supernatant of 
human  PMN  was  around  0.01-0.02  nmol/min  per  mg  of 
protein, which was similar to that observed in rabbit peritoneal 
leukocytes (32).  About 80% of the total activity was recovered 
in the soluble fraction of PMN, and the rest (20%) was consis- 
tently  found  to  be  associated with  the  particulate fraction. 
Tubulin  concentration  as  determined  by  colchicine binding 
activity in the high-speed supernatant fraction was only around 
!% of the total cytoplasmic protein, a  result which has so far 
prevented us from further purification ofPMN tubulin to allow 
us to determine its state of tyrosinolation. However, as in rabbit 
leukocytes, about half of the total colchicine binding activity 
of human PMN  was associated with its particulate fractions. 
Both the distribution and concentration of cellular ligase and 
tubulin were found to be the same in PMN from normals and 
CHS patients and were similar to that observed in other non- 
neuronal ceils (22,  38).  Protein content of normal and  CHS 
PMN were also found to be comparable (data not shown). 
Stimulation of Tyrosine  Incorporation by FMLP 
Fig. 1 shows the basal level ofposttranslational incorporation 
of tyrosine in normal resting PMN and its stimulation induced 
by the peptide chemoattractant FMLP. The incorporation of 
[14C]tyrosine in  unstimulated  PMN  reached  a  plateau  in  90 min, a  result which resembled our earlier observation in neu- 
ronal cells (29). Fig. 1 also shows that the tyrosine incorporation 
was stimulated at the end of 30 min by ~50%  at an  FMLP 
concentration  of  10 -8  M,  and  by  100% at  10  -7  M  FMLP. 
Moreover, unlike in resting PMN, the tyrosine incorporation 
in stimulated cells did not reach a  complete plateau even at 
150 min. Fig. 2 shows the time course of stimulation of tyrosine 
incorporation as induced by FMLP. Unlike in rabbit peritoneal 
leukocytes where we have observed an initial lag of ~6  min 
(32), the chemoattractant caused a rapid stimulation of tyrosine 
incorporation in human PMN. As early as 2 min, the earliest 
time point studied, tyrosine incorporation was stimulated by 
85% above control. 
Basal and FMLP-stimu/ated  Levels  of 
Posnranstational  Tyrosine  Incorporation  and 
Protein  Synthesis  in  Normal and  C/-/S  Cells 
Fig. 3 compares the resting and FMLP-stimulated levels of 
tyrosine incorporation in PMN from normal and CHS patients. 
Basal  levels  of  TCA-precipitable tyrosine  incorporation  in 
PMN from CHSt and CHS2 were about threefold greater than 
that of normal cells. The tyrosine incorporation in PMN of the 
third  CHS  patient (i.e., in  CHSa)  was  about  twofold higher 
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FIGURE  1  Stimulation  of  posttranslational  tyrosine  incorporation 
by FMLP. PMN were preincubated for 30 min at 37°C with antibiotics 
and FMLP concentrations as indicated.  [~4C]tyrosine (5 #Ci ~-- 0.01 
#tool)  was  added  at  0  rain  and  TCA-insoluble  radioactivity  was 
measured at indicated times. The results are means +_SEM of three 
separate experiments. 
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EIGUR[  2  Time-course of stimulation of tyrosine incorporation in- 
duced  by  FMLP.  PMN  at  10  r  cells/ml  were  preincubated  with 
antibiotics  and  10  -7  M  FMLP  and  5 /~Ci of  [14CJtyrosine  (~  0.01 
#mol) were added at 0 time. TCA-insoluble radioactivity was meas- 
ured  at  indicated  times.  The  results  are  the  means  of  duplicate 
determinations. 
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FIGURE  3  Comparison  of  resting  and  FMLP-stimulated  levels of 
tyrosine incorpo[ation in PMN from normal (NL) and three Chediak- 
Higashi syndrome patients (CHSI, CHSe, and  CHSa).  Experimental 
conditions were the same as those described  in  Fig.  1.  Cells were 
preincubated for 30 min with  antibiotics and 10  -7 M  FMLP before 
addition of [14C]tryosine. Values are expressed as means +-SEM for 
three experiments each with CHS~ and CHS2, and for six experiments 
with different normal individuals. The values for CHS3 are means of 
duplicate determinations obtained from a single experiment 
TABLE  I 
Specific Radioactivity of Intracellular Tyrosine Pool in Normal 
and CHS PMN 
Specific 
radioactivity 
Cell sample  Tyrosine 
cpm/ pmol 
Normal-  FMLP  151 
Normal +  FMLP  154 
CHS1 -  FMLP  158 
CHS1 +  FMLP  155 
CHS2-  FMLP  150 
CHS2 +  FMLP  156 
PMN,  at  10Z/ml,  were  preincubated  with  antibiotics  for  30  min  at  37°C  and 
then  further  incubated  in  the  presence  of  [~4C]tyrosine  (5  #Ci/ml  ~  0.01 
#tool)  for  60  rain  in  the  presence  or  absence  of  10  _7  M  FMLP.  Specific 
radioactivity  of  the  intracellular  tyrosine  was  determined  as  described  in 
Materials  and  Methods. 
than  the  normal  resting  levels. The  higher  resting  levels of 
tyrosine  incorporation  in  PMN  of  CHS  patients  could  be 
further stimulated with FMLP, which was quite similar to that 
observed in normal PMN. Control studies, designed to assess 
uptake  rates  in  CHS  and  normal  PMN  using  radiolabeled 
sucrose, did not show any significant differences between nor- 
mal and CHS PMN, a result true for both peptide-stimulated 
and resting cells (data not shown). The rate of protein synthesis 
in the presence or absence of FMLP was similar in both normal 
and  CHS  PMN  as studied by  [14C]leucine  incorporation. In 
addition,  in  parallel  studies,  leucine  incorporation  was  in- 
hibited over 98% when the cells were preincubated with anti- 
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[14C]tyrosine  as measured under our experimental  conditions 
was indeed a  posttranslational  event involving tyrosinolation 
of cellular tubulin (38). 
Specific  Radioactivity of the Intracetlular 
Tyrosine Pool 
Table I shows that the specific radioactivity of the intracel- 
lular tyrosine was similar  in normal and patient cells,  and it 
did not change in the presence of FMLP. These results dem- 
onstrated  that  neither  the  observed  stimulation  of tyrosine 
incorporation  induced  by  FMLP  nor  the  higher  levels  of 
tyrosine incorporation in PMN of CHS patients were attrib- 
utable to a parallel increase in the specific radioactivity of the 
intracellular pool of tyrosine. 
Specific  Tyrosinolation of Tubulin by Intact 
Human PMN 
The specificity of the  reaction  in human  PMN  is  demon- 
strated  in Fig. 4. When an equal amount (-5  x  10  6  cells)  of 
[~4C]tyrosine-labeled  PMN from a normal individual and from 
CHS1  patient were electrophoresed on a  polyacrylamide slab 
gel  and  the  gel  was  subsequently  dried  and  processed  for 
fluorography (24),  radioactivity was detected only in a  single 
protein band corresponding to authentic [14C]tyrosinolated  tu- 
bulin.  Fig. 4 also demonstrates a  significantly higher amount 
of radioactivity in the tubulin band of CHS1  cells  (lane B) as 
compared to that of normal PMN (lane A). Lane C represents 
the electrophoretic mobility of a purified sample of [E4C]tyro- 
sinolated  tubulin  preparation.  Due  to  the  large  amount  of 
PMN protein (-750 #g) that was subjected to gel electropho- 
resis to demonstrate the radioactivity in tubulin bands (Fig. 4), 
the  corresponding  Coomassie  Blue  staining  patterns  of the 
electrophoresed samples were heavily overstained and did not 
resolve into discrete bands and, therefore, are not included in 
the  figure. When the radioactive bands corresponding to tu- 
bulin  (in  lanes  A  and  B)  were  scanned  from  the  original 
fluorogram  and  quantitated  as  described  in  Materials  and 
Methods, the amount of radioactivity in CHS,  cells (lane  B) 
was 2.7 times greater than that of lane A (normal PMN), which 
demonstrates an excellent correlation with the higher levels of 
[~4C]tyrosine incorporated in PMN of CHS1 as shown in Fig. 
3. 
Effect of Ascorbate on Posttranslational Tyrosine 
Incorporation in PMN of CHS Patients 
Although reports on the efficacy of ascorbate administration 
m  correcting some of the  functional  abnormalities  of PMN 
related to CHS have been controversial (5,  15), there is suffi- 
cient evidence in the literature  to suggest that ascorbate pro- 
motes microtubule assembly, both in vivo and in vitro (7), and 
that it corrects defective adherence, chemotaxis, and degranu- 
lation of PMN from CHS patients (5,  18). Since the reaction 
which we are  studying specifically involves cellular tubulin/ 
microtubules, it was of interest to examine the effect of ascor- 
bate on the posttranslational tyrosine incorporation in PMN of 
CHS  patients.  Fig.  5  shows  typical  results  of the  effect  of 
22  - 
FIGURE  4  Quantitative demonstration of the specific incorporation 
of  [~4C]tyrosine  into  tubulin  a-chains  of  normal  and  CHS  PMN. 
Equal amounts of [~4C]labeled  PMN  as obtained  in the experiment 
described  in  Fig.  3  were subjected  to  gel  electrophoresis,  and  the 
slab gel  was processed  for fluorography.  Details of the procedures 
are described in the text. Lane A: normal; Lane B: CHS1;  Lane C: an 
overexposed  sample  of  authentic  assemb[y-purified  [14C]tyrosino- 
lated tubulin  preparation. The upper panel  (in  A  and  B)  represents 
the densitometric  scans of the corresponding  radioactive bands  in 
the lower panel. 
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FIGURE  5  Effect of addition of ascorbate in vitro on the resting and 
FMLP-stimulated  levels  of  tyrosine  incorporation  in  normal  and 
CHS1  PMN.  Where  indicated,  cells  were  preincubated  for  30  min 
with  10 -4  M  ascorbate and  10 -7  M  FMLP was added  at zero  rain. 
Other  experimental  conditions  were  the  same  as  in  Fig.  1.  The 
results are the means of duplicate determinations. 
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PMN from a normal individual and from CHS~. Preincubation 
with  10  -4 M  ascorbate had a profound effect both on the rate 
and the final extent of tyrosine incorporation in PMN of CHS1 
(curve 2),  and  it essentially resembled the incorporation ob- 
served in normal cells (curve 3). Addition of ascorbate also had 
a  small effect on  the  basal level of incorporation in normal 
PMN  (curve 4), which has been consistently reproducible in 
PMN obtained from a  number of different individuals. Most 
strikingly, preincubation  with  10 -4  M  ascorbate  completely 
inhibited the FMLP-induced stimulation of tyrosine incorpo- 
ration, in both normal PMN and in PMN obtained from CHS~. 
Tyrosine incorporation was even less than that in the presence 
of ascorbate  alone.  In  one  experiment,  we  also  studied  the 
effect of in vitro addition of ascorbate in PMN  of CHS2 and 
obtained similar results (data not shown). 
Encouraged by the results reported in Fig. 5, we have also 
studied the effect of oral administration of 8 g of ascorbate to 
the CHS patients on the rate and extent of posttranslational 
tyrosine incorporation in their PMN.  Absorption of ascorbic 
acid from the gastrointestinal tract was documented in each 
patient. Serum ascorbate levels increased from 70 #M/liter to 
205/tM/liter in CHS1 and from 55 ~M/liter to 115 ~tM/liter in 
CHS2 while they were on ascorbate. Fig. 6A demonstrates the 
levels of TCA-insoluble [14C]tryosine  incorporation in PMN of 
CHSz and CHS2 before and 2 h after administration of ascor- 
bate. It clearly shows a  significant effect of ascorbate, which 
was very similar to that  observed in Fig. 5,  where ascorbate 
was added in vitro, to the incubation medium. Fig. 6 B shows 
tyrosine incorporation into PMN of the same CHS patients a 
week after they were withdrawn from ascorbate and demon- 
strates the typical high levels of incorporation as reported in 
Fig. 3. 
In  view  of the  results  presented  in  Fig.  6,  we  have  also 
performed  a  control  experiment  in  which  posttranslational 
incorporation of tyrosine was  studied in  both  normal PMN 
and  in  PMN  from  CHSz.  For  this  experiment,  PMN  were 
preincubated for 1 h in the presence of 10  -4 M  ascorbate and 
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FIGURE  6  Effect  of  administration  of  ascorbate  in  vivo  on  the 
resting levels of posttranslational tyrosine incorporation into  PMN 
of CHS patients. PMN at 10Z/ml were preincubated with antibiotics, 
and  [14C]tyrosine incorporation was  measured at  indicated  times. 
Panel  A:  O  O  and  A  A  represent  preascorbate  levels  of 
tyrosine  incorporation  in  CHSI  and  CH52; H  and  •  • 
represent  the  corresponding  2-h  postascorbate  values.  ~  C> 
shows resting levels of incorporation in  PMN  of a  normal  donor. 
Panel  B  shows the corresponding resting levels of tyrosine incor- 
poration  in  CHSI  and  CHSe 1 wk  after withdrawal  of  ascorbate 
therapy and compares them to the normal levels. The results are the 
means of duplicate determinations. 
then  centrifuged and  resuspended in either fresh incubation 
medium without  ascorbate or in medium containing  10 -4 M 
ascorbate. The effect of ascorbate (as shown in Fig. 5) persisted 
for at least another 90 min after removal of ascorbate from the 
incubation medium. Resting levels of tyrosine incorporation in 
the absence of ascorbate resembled the  incorporation in  the 
presence of ascorbate, a result true in both normal and CHS1 
PMN (data not shown). 
Ascorbate is a  powerful reducing agent. To assess whether 
the ascorbate effect on tubulin tyrosinolation was specific, the 
effect of other reducing  agents  on  both  resting and  FMLP- 
stimulated PMN was studied. Fig. 7 shows that preincubation 
of normal or CHS PMN with other reducing agents, such as 
GSH, cysteine, or DTT, produced effects on tyrosine incorpo- 
ration similar to that ofascorbate (Fig. 5), a result true for both 
resting and FMLP-stimulated PMN. 
Tubulin-specific Particulate  Protease/Peptidase 
Activity of PMN 
Since ligase specific activity was not altered in CHS patients, 
we were interested in measuring the CPT activity (1, 23) which, 
in brain tissue, has been shown to be the major detyrosinolating 
enzyme responsible for the removal of tyrosine from the car- 
boxy-terminus of a-tubulin  (1,  23).  It  was  reasoned  that,  if 
indeed there were a microtubule-related functional abnormal- 
ity in PMN of CHS patients (36), CPT might be altered in such 
cells. Using [~4C]tyrosinolated tubulin (23) as the substrate, the 
release of [I4C] carboxy-terminal tyrosine of tubulin a-chains 
in the presence of high-speed supernatant and pellet fractions 
of PMN obtained from normal and CHS donors was monitored 
(Table II). The major detyrosinolating activity was associated 
with the PMN-particulate fractions, and it was reduced signif- 
icantly  in  CHS  cells.  To  determine  whether  the  observed 
release of radioactivity from [14C]tyrosinolated tubulin was due 
to the presence of CPT (1, 23) in these subcellular fractions or 
if it were due to a more nonspecific proteolytic activity, which 
could also be present in these preparations, three experiments 
were performed to characterize further the nature of this en- 
zymatic activity: (a)  [3H]valine labeled tubulin randomly la- 
beled with [3H]valine via protein synthesis, was  used as the 
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16  16 
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FIGURE  7  Effects  of  various  reducing  agents  on  the  resting  and 
FMLP-stimulated  levels  of  tyrosine  incorporation  in  normal  and 
CHS1 PMN. Where indicated,  PMN were preincubated for 30 rain 
with 10  -a M  GSH, cysteine, or DTT, and 10  -7 M  FMLP was added at 
zero min. Other experimental conditions were the same as in Fig. 1. 
Panel  A:  normal  PMN;  Panel  B:  CHS1 PMN.  The  results  are the 
means of duplicate determinations. 
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Tubulin-specific Peptidase Activity in PMN from Normals and 
CHS Patients 
Sample  Normals*  CHS*  P:~ 
pmol/ rag~  rain 
Supernatant  0.32 ±  0.04  0.26 -4- 0.04  >0.05 
Pellet  4.30 ±  0.40  0.94 ±  0.62  <0.02 
* Data are mean +_SEM  of studies in three different normals  and three separate 
preparations  of  PMN  from  CHS~ and  CHS2 and  three  studies  on  one 
preparation of CHS3. 
:[: Significance  of difference between CHS and normal; Student's t test. 
TASTE III 
Characterization of the Proteolytic Activity Associated with a 
PMN-Particulate Fraction 
[3H]Valine 
[14C]Tyrosine  released 
released 
+150 
Enzyme  mM  Con- 
sample  Control  NaCI  +PMSF  trol  +PMSF 
Purified  CPT  20,000 
PM N-100,000- g  450 
pellet 
cpm/ rag/ rain 
<50  19,900  0  -- 
445  <50  780  <80 
Freshly  separated  PMN  were  suspended  in  tubulin  reassembly  buffer  and 
sonicated  to  disrupt  the  cells  (9).  The  cell  sonicates  were  centrifuged  at 
100,000 g and the resultant pellet fractions were used for the enzyme assay. 
substrate, (b) 150 mM NaCI, which inhibits CPT (28) but not 
neutral  proteases  (4,  12)  was  included  in  the  homogenizing 
medium, and (c) the PMN pellet fractions were preincubated 
for 30 min with 1 mM PMSF, which inhibits neutral proteases 
(4,  12) but not CPT. Using the above criteria, it was concluded 
that the observed release of tyrosine, as reported in Table II, 
was not due primarily to the presence of the specific detyro- 
sinolating CPT (23), as the PMN-preparations released radio- 
activity  in  parallel  from  [3H]valine  labeled  tubulin  as  well. 
Also, as summarized in Table III, the activity was not signif- 
icantly inhibited by either the addition of 150 mM NaC1 or a 
30-rain preincubation at 37°C with I mM PMSF, which caused 
-90% inhibition  of the enzymatic activity without inhibiting 
the purified CPT. 
To assess  the  possibility of whether  the increased  tubulin 
tyrosinolation in PMN from CHS patients was related to the 
decreased proteolysis of tyrosinolated tubulin (Table II), stud- 
ies were done with normal PMN treated with PMSF.  Prein- 
cubation  with  2  mM  PMSF  for  30  rain  at  37°C,  which  is 
sufficient to inhibit  total  PMN  proteolytic activity to >60% 
(41),  did not alter  tyrosine incorporation in either resting or 
FMLP-stimulated cells (data not shown). 
DISCUSSION 
As recently reported for peritoneal rabbit leukocytes (32),  the 
synthetic peptide  chemoattractant,  FMLP,  caused  a  specific, 
dose-dependent  increase  in  the  rate  and  the  final  extent  of 
posttranslational incorporation of tyrosine in peripheral human 
blood PMN (Fig.  1). 
The  basal  level of tyrosine incorporation  in normal PMN 
reached a plateau in 60-90 min (Fig.  1), which resembled our 
earlier  observations  in  neuronal  cells  (29).  As  revealed  by 
fluorography,  the  tyrosine,  which  was  incorporated  in  the 
absence of protein synthesis, was exclusively incorporated into 
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tubulin  a-chains  (Fig.  4),  a  result  true  for both normal and 
CHS cells. The observed stimulation in the presence of FMLP 
was not related to an increased transport of tyrosine into PMN 
nor was it due to a higher specific radioactivity of the intracel- 
lular tyrosine pool (Table I). Although experimental evidence 
suggests that the incorporated tyrosine is essentially all in the 
tubulin  a-chains  (Fig.  4),  we  are  not  sure  whether  we  are 
measuring turnover of preexisting tyrosine or an incremental 
fixation.  We  have  so  far  been  unable  to  chase  any  fixed 
radioactivity from either resting or stimulated PMN even with 
a 1,000-fold excess of [~2C]tyrosine where we have used a pulse 
of 10 nM [aH]tyrosine (sp act, 86 Ci/mmol). This is also true 
in HeLa cells (31) and in rabbit leukocytes (32). This suggests 
that the observed fixation was an incremental incorporation of 
tyrosine rather than a turnover or an exchange of the preexist- 
ing carboxy-terminal tyrosine of tubulin a-chains. Since tyro- 
sinolation in cells is always studied in the absence of protein 
synthesis, it is difficult to correlate posttranslational tyrosino- 
lation of tubulin  in cells (as studied  under our experimental 
conditions) to the recent discovery that some of the tubulin a- 
chain genes encode a carboxy-terminal tyrosine (43). 
Two other important considerations related to the interpre- 
tation of the results presented in this paper are the observations 
that about half of the tubulin from a variety of cells or tissue 
is not a substrate for enzymatic tyrosinolation (30, 31), and, as 
we have observed in brain (30) and also in several cultured cell 
lines (29, 31), at least part of the tubulin tyrosinolated in intact 
cells is a different species from that which can be tyrosinolated 
in vitro (29, 31) and does not seem to be a substrate for ligase 
in vitro. Except in HeLa cells where tubulin comprises -5% of 
the cellular protein (9),  it generally constitutes only  1-2% of 
the  cellular  protein  in other non-neuronal  cells.  Due  to the 
small amount of cellular tubulin in PMN (1% of total protein), 
it has not yet been possible to isolate tubulin in sufficient purity 
to determine  the tyrosine content or the nature  of the tyro- 
sinolated tubulin in these cells. Another issue related to tubulin 
tyrosinolation in ceils  stems from the fact that, in a variety of 
cell lines that we have studied so far (29, 31) and also in human 
PMN and rabbit leukocytes (32), colchicine, podophyllotoxin, 
or nocodazole, which are all microtubule-disrupting agents and 
prevent cytoskeletal reorganization in PMN (26,  36),  did not 
inhibit posttranslational tyrosine fixation (J. Nath, unpublished 
results).  This indicates that neither tubulin tread-milling (27) 
nor intact  microtubules (41)  are required  for the reaction to 
proceed in intact cells. The results also indicate that the micro- 
tubule-related cytoskeletal changes accompanying chemotaxis 
in  PMN  (26,  36)  are  not  necessary  for the  FMLP-induced 
stimulation of tyrosine fixation to occur. 
The abnormally high level of posttranslational tyrosine fix- 
ation in PMN of all three CHS patients studied (Fig. 3) is of 
particular interest. The maj or defects in PMN function of CHS 
have  been  related  to  its  impaired  chemotaxis  and  delayed 
lysosomal degranulation after phagocytosis (10,  17, 39). In the 
present context, the most important morphological features of 
the  PMN  are its  cytoskeletal components, i.e.,  primarily  the 
microtubules and microfilaments, and the plasma membrane. 
Although evidence for a microtubule defect in PMN of CHS 
patients has been controversial and could not be readily dem- 
onstrated by morphologic criteria in the patients presented in 
this  paper  (6,  13,  16,  35,  45),  the  results  presented  in  this 
communication provide evidence for a biochemical alteration 
in the tubulin of these cells.  However, as discussed below, the 
higher levels of tubulin tyrosinolation in PMN of CHS patients may not be a tubulin defect per se but may represent a defect 
in cellular modulation of the reaction, which could be related 
to the increased oxidative metabolism characteristic of these 
cells (40) and subsequent altered redox state. Protein synthesis 
was  found  to  be  normal  in  CHS  cells,  and  uptake  studies 
performed with radiolabeled sucrose in the presence or absence 
of FMLP  did not  show  any  significant differences between 
normal and CHS cells (data not shown). The specific radioac- 
tivity values of the intracellular pool of tyrosine (Table I) also 
demonstrate that the higher levels of posttranslational tyrosine 
incorporation in PMN of CHS1 and CHS2 (in the presence or 
absence of FMLP) is not attributable to a parallel increase in 
the specific radioactivity of free tyrosine in these cells. 
From the specific radioactivity of the tyrosine pool (Table I) 
and the amount of tubulin per milligram soluble protein (i.e., 
I% or ~ 10 #g ~  0.09 nmol/mg), we can calculate the moles 
of tyrosine fixed per mole of tubulin.  In normal PMN,  the 
basal level of tyrosine incorporation (Figs. 1 and 3) corresponds 
to 0.25-0.30 mole of tyrosine per mole of tubulin. In CHS cells, 
the corresponding value ranges from 0.60--0.85  mol/mole of 
tubulin. The latter amount appears rather high to be entirely 
attributable  to  incremental  fixation,  especially because  the 
fixation has not reached a plateau at this point (Fig. 3). 
The proteolytic enzyme, which was not the detyrosinolating 
CPT  (Table  III),  was  primarily associated  with  the  PMN 
particulate fraction (Table II) and was greatly reduced in CHS 
cells; the enzyme has not yet been characterized sufficiently to 
have a functional role assigned for it. Human PMN contain a 
variety of neutral proteases (19) many of which are reported to 
be associated with particulate fractions (19). In addition, Vas- 
sail et  al.  have  reported  a  reduction  in  elastase activity, an 
azurophil granule associated enzyme, in PMN of CHS patients 
(44).  However, the activity reported here is not an elastase type 
neutral protease (4, 44) as, unlike elastase, it did not dissociate 
from  the  particulate fraction  of PMN  and  remained  firmly 
associated with it even after preincubation with 200 mM NaC1 
which solubilizes elastase (4, 12). Its marked reduction in PMN 
of all three CHS patients (Table II) warrants further study of 
the  enzyme  to  better  understand  its  possible role  in  PMN 
function. The increased tubulin tyrosinolation in CHS cells is 
unlikely to be related to the decreased proteolysis since tubulin 
tyrosinolation was not increased in normal PMN treated with 
the proteolytic inhibitor PMSF. However, a possible role of the 
proteolytic enzyme (Table II) cannot be completely ruled out. 
Initially, the effect of ascorbate on both resting and FMLP- 
stimulated posttranslational tyrosine incorporation in PMN of 
CHS1  and  CHS2  (Figs. 5  and  6) was studied in view of the 
reported evidence (7,  18) showing that many of the functional 
abnormalities in CHS  neutrophils, at  least in some patients, 
were correctable by ascorbate.  Moreover,  ascorbate has also 
been shown to promote microtubule assembly and to stimulate 
PMN chemotaxis (7).  The latter effect may not necessarily be 
related to the stimulatory effect of ascorbate on the generation 
of cyclic guanosine monophosphate in these cells (35,  39)  as 
the stimulation of microtubule assembly and  of chemotaxis, 
were reported to occur when nucleotide levels of PMN  were 
only marginally affected  (5).  Since  ascorbate  is  a  powerful 
reducing agent, its therapeutic effect could possibly be related 
to correction of the exaggerated oxidative metabolism in PMN 
of CHS patients (40).  Evidence in support of this possibility 
was  provided by the  studies with  unrelated  reducing  agents 
such  as  GSH,  cysteine,  or  DTT,  which  were  also  found  to 
produce similar effects (as that of ascorbate), on tubulin tyro- 
sinolation in resting and FMLP-stimulated normal and CHS 
PMN (Fig. 7).  Thus,  the effects of ascorbate on tubulin tyro- 
sinolation were not specific, and the results in Fig. 7 suggest a 
correlation between cellular redox and tubulin tyrosinolation 
in PMN. 
The biochemical basis and the specificity of our measured 
levels  of posttranslational  tyrosine  fixation  into  tubulin  a- 
chains (Fig. 4) and its rapid stimulation in the presence of a 
chemoattractant  (Fig.  2)  suggest  a  functional  link  between 
tubulin tyrosinolation and PMN functions, such as chemotaxis, 
degranulation, or superoxide generation, which are stimulated 
by chemoattractants. In view of our results with ascorbate and 
other reducing agents, it is tempting to consider that tyrosino- 
lation of tubulin may be coupled to the early redox changes 
involved in human PMN activation. 
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